Goldman Sachs Group Inc. Increases Stock Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Goldman Sachs Group Inc. lifted its stake in shares of HealthEquity, Inc. (NASDAQ:HQY) by 24.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,129,634 shares of the company’s stock after buying an additional 223,428 shares during the quarter. Goldman Sachs Group Inc. owned about 1.32% of HealthEquity worth $74,895,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of HQY. Janney Montgomery Scott LLC acquired a new position in HealthEquity in the third quarter valued at $217,000. Pathstone Family Office LLC purchased a new stake in shares of HealthEquity in the 3rd quarter valued at about $230,000. Deutsche Bank AG boosted its position in shares of HealthEquity by 8.1% in the 3rd quarter. Deutsche Bank AG now owns 88,349 shares of the company’s stock valued at $6,454,000 after purchasing an additional 6,584 shares during the period. Rhumbline Advisers grew its stake in HealthEquity by 1.0% during the 3rd quarter. Rhumbline Advisers now owns 274,537 shares of the company’s stock worth $20,055,000 after buying an additional 2,800 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in HealthEquity during the third quarter worth approximately $41,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HQY shares. Wells Fargo & Company increased their price objective on HealthEquity from $105.00 to $107.00 and gave the company an “overweight” rating in a report on Tuesday, June 4th. JPMorgan Chase & Co. raised their price objective on shares of HealthEquity from $86.00 to $108.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 2nd. Raymond James lifted their price objective on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Friday, June 7th. BTIG Research increased their target price on shares of HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. Finally, Barrington Research boosted their price target on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.42.

HealthEquity Price Performance

HealthEquity stock opened at $84.37 on Tuesday. The company has a market cap of $7.34 billion, a P/E ratio of 91.71, a price-to-earnings-growth ratio of 1.38 and a beta of 0.55. HealthEquity, Inc. has a one year low of $59.02 and a one year high of $87.72. The business has a fifty day moving average of $80.37 and a two-hundred day moving average of $77.23. The company has a debt-to-equity ratio of 0.44, a quick ratio of 4.39 and a current ratio of 4.39.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.42 by $0.08. HealthEquity had a net margin of 7.71% and a return on equity of 7.77%. The firm had revenue of $262.39 million during the quarter, compared to analysts’ expectations of $258.56 million. As a group, analysts predict that HealthEquity, Inc. will post 2.13 earnings per share for the current fiscal year.

Insider Activity

In related news, Vice Chairman Stephen Neeleman sold 400 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total value of $34,000.00. Following the sale, the insider now owns 90,515 shares in the company, valued at approximately $7,693,775. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Vice Chairman Stephen Neeleman sold 400 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $85.00, for a total value of $34,000.00. Following the sale, the insider now directly owns 90,515 shares in the company, valued at approximately $7,693,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jon Kessler sold 33,765 shares of the firm’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the transaction, the chief executive officer now owns 126,635 shares of the company’s stock, valued at $10,106,739.35. The disclosure for this sale can be found here. In the last three months, insiders sold 68,745 shares of company stock worth $5,482,530. Company insiders own 2.20% of the company’s stock.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.